20 May 2025
Biztonsági szemle
Regeneron commits to 23andMe's privacy policies after $256M buy
U.S. biotechnology firm Regeneron Pharmaceuticals has pledged to adhere to the current privacy policy of 23andMe, which allows consumer deletion of genetic data, as it entered a $256 million agreement to purchase the embattled DNA testing services company's Total Health and Research Services business, Personal Genome Service, biobank, and other assets, reports The Record.
Read more